The Biosimilars LatAm – Brazil 2022 is providing in-depth local analysis and information regarding commercialization strategies, regulation, good manufacturing and distribution practices, international market trends and more.

With a particular focus on providing insight into the clinical practice and prescription of these drugs in the country, seeking for a greater access to biological treatments for patients in Brazil.

Who will
you meet?

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

Biosimilars
Biobetters
Biotechnology
Biotherapeutics
Analytical science
Regulatory compliance
Quality Control
Clinical immunology
Scientific Affairs
Pharmacovigilance
Research
Regulatory
Business Development
Marketing

Speaker Board

Program at a Glance

Greater Access to Safe and Effective Life- saving Medications

Tendering Procedures: Healthy Competition and Public Health

GVP Case Study for an Specific Disease

The best-practices and improvement overview directly from Healthcare professionals to secure the traceability of medicaments and ability to track the patient’s medical journey. Securing the ability to reacting promptly in case any adverse-effects happen and be able to change the cure knowing exactly the root of the problem

Self-awareness Education: Patient Centered Communication

Regulatory Convergence and Harmonization

Prescribing Behaviours of Biosimilar Medicines

Full programme in the PDF Agenda

Download Agenda

Download Agenda

Pall

Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies.

Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste.

Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation .

Visit Website

Cytiva

Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.

Visit Website

Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Visit Website

Merck

We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.

Visit Website

Terumo

We develop alliances with pharmaceutical companies, using Terumo technology to develop, manufacture and supply solutions to injectable drug delivery challenges. We pride ourselves on offering a portfolio of products and services for the pharmaceutical industry. By anticipating trends and maintaining a constant dialogue, we provide a first class customer experience.

Visit Website

Thermo Fisher

Thermo Fisher Scientific is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Visit Website

Unizima

Unizima delivers international biomanufacturing projects from inception to technology transfer and validation. We bring together all the elements needed to make the project a reality, we manage it and offer operational support to ensure successful continued operation. Our operational support services cover quality control, supply chain, and digital oversight. We also devise and implement bioproduction training programs, and design and build care centers and diagnostics surveillance centers.

By connecting these local production facilities with health expertise and infrastructure, we are able to deliver life-changing biologics to people in low-to-middle income countries.

Visit Website

Sponsor the Forum

Photo Gallery from Previous Events

Open Gallery

Testimonials

”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”

Alison Bascou, Sr. Regulatory Director at BD, France
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."

Jaime Uribe, CEO At PROBIOMED
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”

Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”

Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”

Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico